Xu Yan, Wang Meng-Chuan
Department of Pharmacy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Department of Pharmacy, Affiliated Cixi Hospital, Wenzhou Medical University, Ningbo, China.
Gut Microbes. 2025 Dec;17(1):2560695. doi: 10.1080/19490976.2025.2560695. Epub 2025 Sep 15.
Breast cancer remains a leading global malignancy among women, with increasing incidence and mortality. Recent advances in multi-omics technologies have revealed the presence of diverse microbial communities in the tumor microenvironment, comprising bacteria, viruses, and fungi. These microbes play complex roles within tumor initiation and progression, affecting local inflammation and modulating host metabolism, genomic stability, and immune responses. Emerging evidence indicates that the intratumoral microbiota holds diagnostic potential and represents a novel biomarker for molecular subtyping and prognosis. Furthermore, intratumoral microbiota offer new avenues for targeted interventions, such as engineered bacteria and phage therapy, which may overcome limitations of conventional treatments. This review summarizes current insights into the composition, colonization pathways, mechanisms, and clinical applications of intratumoral microbiota, underscoring their potential to advance precision medicine in breast cancer.
乳腺癌仍然是全球女性中主要的恶性肿瘤,其发病率和死亡率不断上升。多组学技术的最新进展揭示了肿瘤微环境中存在多种微生物群落,包括细菌、病毒和真菌。这些微生物在肿瘤的发生和发展中发挥着复杂的作用,影响局部炎症并调节宿主代谢、基因组稳定性和免疫反应。新出现的证据表明,肿瘤内微生物群具有诊断潜力,是分子亚型和预后的新型生物标志物。此外,肿瘤内微生物群为靶向干预提供了新途径,如工程菌和噬菌体疗法,这可能克服传统治疗的局限性。本综述总结了目前对肿瘤内微生物群的组成、定植途径、机制和临床应用的见解,强调了它们在推进乳腺癌精准医学方面的潜力。